Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Heart Failure - Systolic Dysfunction

Heart Failure - Systolic Dysfunction 1 Quality Department Guidelines for Clinical Care Ambulatory Heart Failure Guideline Team Team Leader William E Chavey, MD Family Medicine Team Members Barry E Bleske, PharmD Pharmacy R Van Harrison, PhD Medical Education Robert V Hogikyan, MD, MPH Geriatric Medicine Yeong Kwok, MD General Medicine John M Nicklas, MD Cardiology Consultant Todd M Koelling, MD Cardiology Initial Release August, 1999 Most Recent Major Update August, 2013 Interim/Minor Revision (...) December, 2016 Ambulatory Clinical Guidelines Oversight Grant Greenberg, MD, MA, MHSA R Van Harrison, PhD Literature search service Taubman Health Sciences Library For more information: 734-936-9771 Heart Failure - Systolic Dysfunction Patient population: Adult patients with left ventricular systolic dysfunction Objectives: 1) To improve mortality and morbidity for patients with heart failure (HF). 2) To present a framework for treating patients with HF. Key Points Diagnosis. ? Ejection fraction (EF

2020 University of Michigan Health System

2. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction (Abstract)

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal (...) function in patients with acute heart failure and renal dysfunction at presentation.This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-guided group (n = 79) and in clinical evaluation in the usual-care group (n = 81). Changes in estimated glomerular filtration rate (eGFR) at 72 and 24 hours were the co-primary endpoints, respectively.The mean age

2020 EvidenceUpdates

3. Natriuretic peptide testing for the diagnosis of heart failure

Natriuretic peptide testing for the diagnosis of heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2020 PROSPERO

4. Psychological factors and new onset of heart failure in community populations: a systematic review and meta-analysis of prospective cohort studies

Psychological factors and new onset of heart failure in community populations: a systematic review and meta-analysis of prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

5. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Am J Cardiol Actions 2019 Nov 19 [Online ahead of print] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Warren Alpert School of Brown University

2020 EvidenceUpdates

6. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial

Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions , 140 (23), 1881-1891 2019 Dec 3 Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation

2020 EvidenceUpdates

7. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Full Text available with Trip Pro

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine (...) Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions , 74 (23), 2893-2904 2019 Dec 10 Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Centre of Cardiovascular Research and Education

2020 EvidenceUpdates

8. Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer?

Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer? Heart Failure with Preserved Ejection Fraction: Are Angiotensin Receptor-Neprilysin Inhibitors the Answer? – Clinical Correlations Search Heart Failure with Preserved Ejection Fraction: Are Angiotensin Receptor-Neprilysin Inhibitors the Answer? January 15, 2020 6 min read By Jad Malas Peer Reviewed According to a 2016 American Heart Association (AHA) report, an estimated 5.7 million (...) Americans over the age of twenty have heart failure. . 1 The AHA and American College of Cardiology Foundation (ACCF) divide heart failure into two categories based upon left ventricular ejection fraction (LVEF): an LVEF < 40% is considered heart failure with reduced ejection fraction (HFrEF), while . 2 HFpEF patients make up approximately half of the total heart failure population, and with an aging population this proportion is expected to increase, as over 90% of patients . 3 Despite the growing

2020 Clinical Correlations

9. Shenmai injection for heart failure: a systematic review and trial sequential analysis

Shenmai injection for heart failure: a systematic review and trial sequential analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

10. Shengmai injection for the treatment of chronic heart failure: a systematic review and meta-analysis

Shengmai injection for the treatment of chronic heart failure: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

11. Evaluating the role of chloride levels in heart failure: a systematic review and meta analysis

Evaluating the role of chloride levels in heart failure: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

12. Barriers and facilitators to optimising heart failure management in ethnic minorities: a qualitative systematic review

Barriers and facilitators to optimising heart failure management in ethnic minorities: a qualitative systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

13. L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Full Text available with Trip Pro

L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Coronary artery bypass grafting reduces plasma L-carnitine and may impair the production of myocardial energy. L-carnitine supplementation may elevate plasma L-carnitine and increase cardiac mechanical efficiency. The objective of this study was to verify the recovery of preoperative plasma LC in patients with heart failure undergoing coronary artery (...) bypass grafting supplemented with a daily oral dose of 50 mg / kg. Volunteers with ischemic heart failure who underwent surgery were randomized into a supplemented group (A-received 50 mg / kg L-carnitine) or placebo group (B) for 60 days. Supplementation was started on the third postoperative day. The spectrophotometric enzymatic method was used to quantify plasma L-carnitine. In the preoperative period, both groups had plasma L-carnitine adequate to the reference range (18.9-71.1 μM). On the second

2019 Anais da Academia Brasileira de Ciencias Controlled trial quality: uncertain

14. Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Hello Guest! Login to your account Email Password Keep me logged in Search 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. No Access article Share on Jump to No Access article (...) , MD, FAHA, Chair , MD, FAHA, Vice Chair , MD, PhD, FRCPC, FAHA , MD, PhD , MD, MS, FAHA , MD, MS, FAHA , PhD, RN, FAHA , MD , MD, PhD, FAHA Sharon Cresci , Naveen L. Pereira , Ferhaan Ahmad , Mirnela Byku , Lisa de las Fuentes , David E. Lanfear , Carolyn M. Reilly , Anjali T. Owens , Matthew J. Wolf , Originally published 12 Sep 2019 Circulation: Genomic and Precision Medicine. 2019;12:458–485 Abstract One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better

2019 American Heart Association

15. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure (Abstract)

Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heart failure patients from January 1996 through August 2019. Nineteen studies (9 (...) randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status

2019 EvidenceUpdates

16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Full Text available with Trip Pro

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF

2019 EvidenceUpdates

17. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

Type 2 Diabetes Mellitus and Heart Failure Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March (...) 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update , MD, MS, Co-Chair , MD, FAHA, Co-Chair , MD, FAHA , MD, MHS, FAHA

2019 American Heart Association

18. Improving Communication in Heart Failure Patient Care (Abstract)

Improving Communication in Heart Failure Patient Care Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heart failure (HF) or other diseases. To prevent shocks at the end of life, clinicians should discuss deactivating the defibrillation function.The purpose of this study was to determine if a clinician-centered teaching intervention and automatic reminders increased ICD deactivation discussions and increased device deactivation.In this 6-center

2019 EvidenceUpdates

19. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study (Abstract)

Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk.All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using

2019 EvidenceUpdates

20. Sacubitril/valsartan for chronic heart failure with reduced ejection fraction

Sacubitril/valsartan for chronic heart failure with reduced ejection fraction '); } else { document.write(' '); } ACE | Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Search > > Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction - Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has (...) not recommended listing sacubitril/valsartan on the Medication Assistance Fund (MAF) for treating chronic heart failure with reduced ejection fraction because of uncertain cost-effectiveness and budget impact at the price proposed by the manufacturer. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)